🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06405711
Starting soon Not applicable

To Evaluate the Efficacy and Safety of an Defocus Lens in Slowing the Progression of Myopia

NCT06405711 · tracked via the Priya Life Science China tracker
Sponsor
Tianjin Eye Hospital
Phase
Not applicable
Started
2024-05
Last updated
2024-05-08

Condition(s) studied

Myopia, Progressive

Investigational drug(s) / intervention(s)

frame lens

frame lens: A randomized block group design was used to randomly assign the included study subjects. The appropriate randomization number and random allocation scheme will be given after enrollment.

Study summary

To confirm the efficacy of DIMS lenses in controlling myopia progression, we planned a prospective, single-centre, randomised, double-blind, controlled, non-inferiority clinical study.

Eligibility

Sex
ALL
Min age
8 Years
Max age
13 Years
Healthy volunteers
Accepted
Inclusion Criteria: * The subjects had spherical RE of -1.00 to -6.00 D, astigmatism ≤ 1.50 D, anisometropia ≤ 1.50 D * the best corrected visual acuity in the left and right eyes subjective optometry is greater than or equal to 1.0 Exclusion Criteria: * Candidate subjects were excluded from the study if they had strabismus, ocular limitations, or systemic abnormalities affecting vision and ocular motility

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tianjin Eye Hospital Tianjin China

More Tianjin Eye Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06405711 on ClinicalTrials.gov ↗ ← All trials in China